Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.44
SVA's Cash-to-Debt is ranked lower than
75% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. SVA: 1.44 )
Ranked among companies with meaningful Cash-to-Debt only.
SVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.48  Med: 2.18 Max: N/A
Current: 1.44
Equity-to-Asset 0.56
SVA's Equity-to-Asset is ranked lower than
59% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. SVA: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
SVA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41  Med: 0.58 Max: 0.64
Current: 0.56
0.41
0.64
Piotroski F-Score: 2
Altman Z-Score: 2.70
Beneish M-Score: -2.66
WACC vs ROIC
4.87%
-7.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -10.48
SVA's Operating Margin % is ranked higher than
67% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. SVA: -10.48 )
Ranked among companies with meaningful Operating Margin % only.
SVA' s Operating Margin % Range Over the Past 10 Years
Min: -42.98  Med: 5.73 Max: 50.06
Current: -10.48
-42.98
50.06
Net Margin % -7.09
SVA's Net Margin % is ranked higher than
68% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. SVA: -7.09 )
Ranked among companies with meaningful Net Margin % only.
SVA' s Net Margin % Range Over the Past 10 Years
Min: -30.18  Med: -1.42 Max: 23.7
Current: -7.09
-30.18
23.7
ROE % -3.80
SVA's ROE % is ranked higher than
72% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. SVA: -3.80 )
Ranked among companies with meaningful ROE % only.
SVA' s ROE % Range Over the Past 10 Years
Min: -12  Med: -0.67 Max: 33.16
Current: -3.8
-12
33.16
ROA % -2.28
SVA's ROA % is ranked higher than
76% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. SVA: -2.28 )
Ranked among companies with meaningful ROA % only.
SVA' s ROA % Range Over the Past 10 Years
Min: -7  Med: -0.38 Max: 17.45
Current: -2.28
-7
17.45
ROC (Joel Greenblatt) % -5.59
SVA's ROC (Joel Greenblatt) % is ranked higher than
75% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. SVA: -5.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -27  Med: 5.76 Max: 137.02
Current: -5.59
-27
137.02
3-Year Revenue Growth Rate 10.10
SVA's 3-Year Revenue Growth Rate is ranked higher than
59% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. SVA: 10.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 18.5 Max: 82.5
Current: 10.1
0
82.5
3-Year EPS without NRI Growth Rate -66.70
SVA's 3-Year EPS without NRI Growth Rate is ranked lower than
96% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. SVA: -66.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -13.9 Max: 141
Current: -66.7
0
141
GuruFocus has detected 3 Warning Signs with Sinovac Biotech Ltd $SVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

SVA Guru Trades in Q1 2016

Jim Simons 1,334,600 sh (-1.44%)
» More
Q2 2016

SVA Guru Trades in Q2 2016

Jim Simons 1,396,100 sh (+4.61%)
» More
Q3 2016

SVA Guru Trades in Q3 2016

Jim Simons 1,475,000 sh (+5.65%)
» More
Q4 2016

SVA Guru Trades in Q4 2016

Jim Simons 1,524,800 sh (+3.38%)
» More
» Details

Insider Trades

Latest Guru Trades with SVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:AMEX:BTX, NAS:BSTC, NAS:CASC, NAS:ANIP, NAS:BDSI, NAS:BCRX, NAS:BMRN » details
Traded in other countries:SVQ.Germany,
Sinovac Biotech Ltd is a biopharmaceutical company engaged in research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases.

Sinovac Biotech Ltd, formerly known as Net-Force System Inc., was incorporated in Antigua and Barbuda on March 1, 1999. The Company is an integrated China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A, hepatitis A and B, seasonal influenza, H5N1 and H1N1 pandemic influenza and mumps, as well as animal rabies vaccine. The Company is engaged in the development, manufacturing and sales of vaccines for infectious diseases. Its product consist of Healive, for the treatment of Hepatitis A; Bilive, for the treatment of Hepatitis A&B; Anflu, for the treatment of Influenza; Panflu Whole Viron Pandemic Influenza Vaccine, for Pandemic Influenza Virus; Split Viron Pandemic Influenza Vaccine, for the treatment of Pandemic Influenza Virus; Panflu.1, for the treatment of Influenza A H1N1 virus; RabEnd, for the treatment of Rabies Virus in animals; Mumps Vaccine, for the treatment of mumps; EV71 Vaccine, Pneumococcal Polysaccharide Vaccine, Varicella Vaccine, for the treatment of varicella-zoster virus, H7N9 Vaccine, for the treatment of H7N9 influenza. The Company has four manufacturing bases located in Haidian and Changping Districts of Beijing, Dalian City of Liaoning Province, and Tangshan City of Hebei Province and also has two upstream production facilities in Haidian District, Beijing. It has built a new production site in in Changping District, Beijing, which comprises a new filing and packaging line that complies with the new PRC GMP standards, EV71 production facilities and a warehouse. The Company relies on its sales force to sell its products directly to CDCs in the private market. As of December 31, 2013, the in-house sales and marketing team consisted of 170 staff members located in 31 provinces throughout China. The Company obtains the raw materials from local and overseas suppliers. It maintains two suppliers for each key raw material, with the exception of hepatitis B antigens for Bilive production. The hepatitis B antigens are sourced from Beijing Temple of Heaven. The Company competes with Kunming Institute of Biological Product, Pukang Biological Co., Ltd., Changchun Institute of Biological Products and Changchun Changsheng Life Sciences Ltd for hepatitis A vaccine. It competes with Hualan Biological Engineering Inc., Changchun Institute of Biological Products, GSK, Aleph Biological Co., Ltd. and Zhejiang Tianyuan for influenza vaccines. The Company is subject to PRC laws and regulations governing the use, manufacture, storage, handling or disposal of hazardous materials and waste products.

Ratios

vs
industry
vs
history
PB Ratio 2.91
SVA's PB Ratio is ranked higher than
60% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. SVA: 2.91 )
Ranked among companies with meaningful PB Ratio only.
SVA' s PB Ratio Range Over the Past 10 Years
Min: 0.73  Med: 2.42 Max: 9.91
Current: 2.91
0.73
9.91
PS Ratio 5.13
SVA's PS Ratio is ranked higher than
72% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. SVA: 5.13 )
Ranked among companies with meaningful PS Ratio only.
SVA' s PS Ratio Range Over the Past 10 Years
Min: 0.97  Med: 4.5 Max: 17.54
Current: 5.13
0.97
17.54
Shiller PE Ratio 110.37
SVA's Shiller PE Ratio is ranked lower than
76% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 52.28 vs. SVA: 110.37 )
Ranked among companies with meaningful Shiller PE Ratio only.
SVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 81.33  Med: 122.75 Max: 519
Current: 110.37
81.33
519
Current Ratio 1.91
SVA's Current Ratio is ranked lower than
76% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. SVA: 1.91 )
Ranked among companies with meaningful Current Ratio only.
SVA' s Current Ratio Range Over the Past 10 Years
Min: 1.16  Med: 2.46 Max: 6.15
Current: 1.91
1.16
6.15
Quick Ratio 1.61
SVA's Quick Ratio is ranked lower than
74% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. SVA: 1.61 )
Ranked among companies with meaningful Quick Ratio only.
SVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.18 Max: 5.43
Current: 1.61
0.85
5.43
Days Inventory 344.50
SVA's Days Inventory is ranked lower than
87% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. SVA: 344.50 )
Ranked among companies with meaningful Days Inventory only.
SVA' s Days Inventory Range Over the Past 10 Years
Min: 125.96  Med: 201.85 Max: 389.63
Current: 344.5
125.96
389.63
Days Sales Outstanding 271.05
SVA's Days Sales Outstanding is ranked lower than
95% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. SVA: 271.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
SVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 108.21  Med: 176.39 Max: 271.05
Current: 271.05
108.21
271.05

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.10
SVA's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. SVA: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -70.9  Med: -6.25 Max: -0.6
Current: -1.1
-70.9
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 8.91
SVA's Price-to-Net-Current-Asset-Value is ranked lower than
68% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. SVA: 8.91 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SVA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.06  Med: 6.56 Max: 50.13
Current: 8.91
2.06
50.13
Price-to-Tangible-Book 2.87
SVA's Price-to-Tangible-Book is ranked higher than
67% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. SVA: 2.87 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SVA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.9  Med: 2.59 Max: 17.43
Current: 2.87
0.9
17.43
Price-to-Median-PS-Value 1.14
SVA's Price-to-Median-PS-Value is ranked lower than
59% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. SVA: 1.14 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 1.06 Max: 35.2
Current: 1.14
0.28
35.2
Earnings Yield (Greenblatt) % -1.75
SVA's Earnings Yield (Greenblatt) % is ranked higher than
69% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. SVA: -1.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.77  Med: 5.2 Max: 53.8
Current: -1.75
-1.77
53.8

More Statistics

Revenue (TTM) (Mil) $64.02
EPS (TTM) $ -0.08
Beta0.38
Short Percentage of Float1.98%
52-Week Range $5.25 - 6.45
Shares Outstanding (Mil)56.91
» More Articles for SVA

Headlines

Articles On GuruFocus.com

More From Other Websites
Sinovac Amends Shareholder Rights Plan Mar 24 2017
Sinovac Biotech Ltd. breached its 50 day moving average in a Bearish Manner : SVA-US : March 23,... Mar 23 2017
Sinovac Biotech Ltd. breached its 50 day moving average in a Bearish Manner : SVA-US : March 7, 2017 Mar 07 2017
Sinovac Biotech Ltd. – Value Analysis (NASDAQ:SVA) : January 13, 2017 Jan 13 2017
Sinovac Biotech Ltd. breached its 50 day moving average in a Bullish Manner : SVA-US : January 12,... Jan 12 2017
INVESTOR ALERT: Lundin Law PC Announces an Investigation of Sinovac Biotech Ltd. and Encourages... Jan 11 2017
SINOVAC NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Jan 08 2017
INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sinovac Biotech... Jan 06 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sinovac Biotech... Jan 04 2017
SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Sinovac Biotech Ltd. and Encourages... Dec 23 2016
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Sinovac Biotech Ltd. Investors Dec 23 2016
Sinovac Responds to Recent Report Dec 23 2016
Sinovac Responds to Recent Report Dec 23 2016
Is Sinovac Biotech Ltd. (SVA) A Good Stock to Buy? Dec 22 2016
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Sinovac Biotech Ltd. and... Dec 21 2016
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sinovac Biotech... Dec 21 2016
INVESTOR LOSS ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Sinovac... Dec 21 2016
Sinovac Biotech Ltd. breached its 50 day moving average in a Bearish Manner : SVA-US : December 16,... Dec 16 2016
ETFs with exposure to Sinovac Biotech Ltd. : December 14, 2016 Dec 14 2016
Is Boingo Wireless Inc (WIFI) A Good Stock To Buy? Dec 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)